# Stem Cell Therapy Combined Hormone Replacement Therapy in Patients With Premature Ovarian Failure

> **NCT01742533** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Shenzhen Beike Bio-Technology Co., Ltd.** · enrollment: 40 (estimated)

## Conditions studied

- Premature Ovarian Failure，

## Interventions

- **BIOLOGICAL:** human umbilical cord mesenchymal stem cells
- **BIOLOGICAL:** hUCMSCs and hCBMNCs
- **BIOLOGICAL:** human cord blood mononuclear cells
- **DRUG:** Hormone Replacement Therapy

## Key facts

- **NCT ID:** NCT01742533
- **Lead sponsor:** Shenzhen Beike Bio-Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-03
- **Primary completion:** 2013-06
- **Final completion:** 2014-03
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2012-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01742533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01742533, "Stem Cell Therapy Combined Hormone Replacement Therapy in Patients With Premature Ovarian Failure". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01742533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*